Assignee
BioNTech SE
DE·48 granted patents·93 pending applications·58 citations·filing 2014–2025
Top patents by PatentIndex Score
141 records- 0194US11547673B1Coronavirus vaccineBioNTech SE·Filed 2021·Granted Jan 10, 2023·12 cites·45 claims
- 0292US11878055B1Coronavirus vaccineBioNTech SE·Filed 2023·Granted Jan 23, 2024·2 cites·30 claims
- 0392US11779659B2RNA constructs and uses thereofBioNTech SE·Filed 2021·Granted Oct 10, 2023·4 cites·22 claims
- 0490US12059498B2Preparation and storage of liposomal RNA formulations suitable for therapyBioNTech SE·Filed 2021·Granted Aug 13, 2024·3 cites·26 claims
- 0589US11925694B2Coronavirus vaccineBioNTech SE·Filed 2022·Granted Mar 12, 2024·1 cites·36 claims
- 0689US11559587B2RNA formulation for immunotherapyBioNTech SE·Filed 2019·Granted Jan 24, 2023·3 cites·44 claims
- 0789US11395799B2Preparation and storage of liposomal RNA formulations suitable for therapyBioNTech SE·Filed 2018·Granted Jul 26, 2022·7 cites·31 claims
- 0889US11222711B2Predicting immunogenicity of T cell epitopesBioNTech SE·Filed 2014·Granted Jan 11, 2022·11 cites·34 claims
- 0989US2026085126A1Agonistic tnf receptor binding agentsBioNTech SE·Filed 2025·Application pending·0 cites
- 1088US11987569B2Substituted imidazoquinolines as agonists of TLR7BioNTech SE·Filed 2022·Granted May 21, 2024·1 cites·16 claims
- 1187US12421319B2Binding agents that bind OX40 (CD134) and method of use thereof to treat diseaseBioNTech SE·Filed 2023·Granted Sep 23, 2025·0 cites·11 claims
- 1287US12270813B2Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapyBioNTech SE·Filed 2018·Granted Apr 8, 2025·2 cites·26 claims
- 1387US12054485B2Substituted imidazoquinolinesBioNTech SE·Filed 2022·Granted Aug 6, 2024·1 cites·8 claims
- 1487US11951185B2RNA constructs and uses thereofBioNTech SE·Filed 2021·Granted Apr 9, 2024·1 cites·49 claims
- 1586US11267813B2Substituted imidazoquinolinesBioNTech SE·Filed 2018·Granted Mar 8, 2022·3 cites·4 claims
- 1686US2026049112A1Tumor Antigens for Determining Cancer TherapyBioNTech SE·Filed 2025·Application pending·0 cites
- 1786US2025242059A1Coronavirus vaccineBioNTech SE·Filed 2024·Application pending·0 cites
- 1885US12460198B2Method for reducing immunogenicity of RNABioNTech SE·Filed 2023·Granted Nov 4, 2025·0 cites·19 claims
- 1984US2024124609A1Human monoclonal antibodies to ganglioside gd2BioNTech SE·Filed 2023·Application pending·0 cites
- 2083US12385049B2Modification of RNA, producing an increased transcript stability and translation efficiencyBioNTech SE·Filed 2022·Granted Aug 12, 2025·0 cites·30 claims
- 2183US2024390524A1Rna constructs and uses thereofBioNTech SE·Filed 2024·Application pending·0 cites
- 2281US12133899B2Coronavirus vaccineBioNTech SE·Filed 2022·Granted Nov 5, 2024·0 cites·24 claims
- 2380US12410221B2Tumor antigens for determining cancer therapyBioNTech SE·Filed 2023·Granted Sep 9, 2025·0 cites·13 claims
- 2480US11504419B2Individualized vaccines for cancerBioNTech SE·Filed 2018·Granted Nov 22, 2022·1 cites·33 claims
- 2580US2025011797A1Stabilization of poly(a) sequence encoding dna sequencesBioNTech SE·Filed 2024·Application pending·0 cites
- 2679US12208136B2Coronavirus vaccineBioNTech SE·Filed 2023·Granted Jan 28, 2025·0 cites·28 claims
- 2779US11046745B2Peptide mimotopes of the CD3 T-cell co-receptor epsilon chain and uses thereofBioNTech SE·Filed 2015·Granted Jun 29, 2021·3 cites·38 claims
- 2879US2026071201A1Methods for Providing Single-Stranded RNABioNTech SE·Filed 2025·Application pending·0 cites
- 2978US2025283888A1Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapyBioNTech SE·Filed 2024·Application pending·0 cites
- 3077US2022257783A1Recombinant vaccines and use thereofBioNTech SE·Filed 2022·Application pending·0 cites
- 3176US11760809B2Human monoclonal antibodies to ganglioside GD2BioNTech SE·Filed 2020·Granted Sep 19, 2023·0 cites·10 claims
- 3276US11279684B2Substituted imidazoquinolines as agonists of TLR7BioNTech SE·Filed 2018·Granted Mar 22, 2022·1 cites·15 claims
- 3376US2025108008A1Preparation and storage of liposomal rna formulations suitable for therapyBioNTech SE·Filed 2024·Application pending·0 cites
- 3475US12378531B2Use of RNA for reprogramming somatic cellsBioNTech SE·Filed 2021·Granted Aug 5, 2025·0 cites·9 claims
- 3575US2023406902A1Peptide mimotopes of claudin 18.2 and uses thereofBioNTech SE·Filed 2023·Application pending·0 cites
- 3674US11814411B2Nucleic acid molecules encoding binding agents to CD40 and 4-1BB (CD137)BioNTech SE·Filed 2021·Granted Nov 14, 2023·0 cites·14 claims
- 3773US12186387B2Coronavirus vaccineBioNTech SE·Filed 2022·Granted Jan 7, 2025·0 cites·28 claims
- 3873US2024366751A1Coronavirus vaccineBioNTech SE·Filed 2023·Application pending·0 cites
- 3972US11873478B2Method for reducing immunogenicity of RNABioNTech SE·Filed 2020·Granted Jan 16, 2024·0 cites·20 claims
- 4072US10927181B2Agonistic tumor necrosis factor (TNF) receptor binding agentsBioNTech SE·Filed 2019·Granted Feb 23, 2021·0 cites·20 claims
- 4171US11492628B23′-UTR sequences for stabilization of RNABioNTech SE·Filed 2016·Granted Nov 8, 2022·1 cites·73 claims
- 4271US2025213599A1Formulation for administration of rnaBioNTech SE·Filed 2024·Application pending·0 cites
- 4371US2023190898A1Individualized vaccines for cancerBioNTech SE·Filed 2022·Application pending·0 cites
- 4470US12516333B23′-UTR sequences for stabilization of RNABioNTech SE·Filed 2022·Granted Jan 6, 2026·0 cites·20 claims
- 4570US12263215B2Cytotoxic immunostimulating particles and uses thereofBioNTech SE·Filed 2021·Granted Apr 1, 2025·0 cites·19 claims
- 4670US12168051B2Methods and compositions for stimulating immune responseBioNTech SE·Filed 2022·Granted Dec 17, 2024·0 cites·24 claims
- 4770US11673939B2Compositions and methods for diagnosis and treatment of cancerBioNTech SE·Filed 2019·Granted Jun 13, 2023·1 cites·19 claims
- 4870US2022249372A1Lipid Particle Formulations for Delivery of RNA and Water-Soluble Therapeutically Effective Compounds to a Target CellBioNTech SE·Filed 2022·Application pending·0 cites
- 4970US2024158501A1Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseasesBioNTech SE·Filed 2023·Application pending·0 cites
- 5069US12281322B2RNA replicon for versatile and efficient gene expressionBioNTech SE·Filed 2021·Granted Apr 22, 2025·0 cites·13 claims
Showing the top 50 of 141 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when BioNTech SE files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →